January 5, 2024 · Form 4 insider transaction
Casdin Partners Master Fund, L.P. bought 2,744,219 shares of Standard BioTools Inc., a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. Per the terms of the Merger, each share of SomaLogic common stock was converted pursuant to the Exchange Ratio at the Effective Time. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.